Carilion Clinic | Research and Development
Status and phase
Conditions
Treatments
About
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Written and voluntarily given Informed Consent.
Male or female ≥18 years of age at time of consent.
Have the capacity to understand the study and be willing and able to comply with all protocol requirements.
Participants must have histologically or cytologically proven solid tumors of the following types, but not limited to:
At least one non-CNS, measurable target lesion as per RECIST 1.1 documented at conventional imaging, performed within 30 days prior to Day 0.
Participant agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form (ICF) until completion of the last study visit.
Negative serum pregnancy tests in female patients of childbearing potential at screening and confirmation of negative pregnancy test result from urine within24 hours prior to receiving investigational product. Female patients of non-child-bearing potential must provide evidence by fulfilling one of the following criteria at screening:
For all participants, consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-girentuximab administration.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Kavita Vadali
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal